Jenna Karpel

A partnership Leica Biosystems, Indica Labs, and Lunit that will focus on PD-L1 and emerging immunohistochemistry (IHC) biomarkers, supporting scalable and consistent biomarker quantification through computational pathology tools. The first product is an AI-powered Lunit SCOPE algorithm designed for Leica Biosystems’ PD-L1 primary antibody (CAL10).

Industry Leaders Leica Biosystems, Indica Labs and Lunit Partner to Develop AI-Powered Computational Pathology Assays for PD-L1 and Emerging Biomarkers

HALO AP, News, Press Releases /

VISTA, California, ALBUQUERQUE, New Mexico, and SEOUL, South Korea — May 26, 2026 — Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions, and Indica Labs, a global leader in AI-powered digital pathology software, today announced a strategic collaboration with Lunit (KRX:328130.KQ), a leading provider of AI solutions for cancer diagnostics and therapeutics, to develop AI-powered image analysis algorithms. The partnership will focus on PD-L1 and emerging immunohistochemistry (IHC) biomarkers, supporting scalable and consistent biomarker quantification through computational pathology tools. The first product is an AI-powered Lunit SCOPE algorithm designed for Leica Biosystems’ PD-L1 primary antibody (CAL10). The new algorithm, Lunit SCOPE PD-L1 CAL10 NSCLC1, is now available through Leica Biosystems’ Aperio AI Store.

Industry Leaders Leica Biosystems, Indica Labs and Lunit Partner to Develop AI-Powered Computational Pathology Assays for PD-L1 and Emerging Biomarkers Read More »

Leica Biosystem and Indica Labs combined Aperio HALO AP DX and Aperio GT 450 DX Scanner for a complete clinical digital pathology ecosystem

Leica Biosystems and Indica Labs Expand Digital Pathology-Powered Diagnostics in the USA with Aperio HALO AP DX Software Launch

HALO AP, HALO AP Dx, News, Press Releases / , , ,

Vista, CA, and Albuquerque, NM, March 31, 2026 – Leica Biosystems, a Danaher company and a global leader in anatomic and digital pathology solutions, and Indica Labs, a global leader in artificial intelligence (AI)-powered digital pathology software, launches Aperio HALO AP DX image management system designed for use with the Aperio GT 450 DX scanner. Together, the Aperio HALO AP DX software and the Aperio GT 450 DX scanner provide a complete, integrated clinical digital pathology solution supporting on‑screen diagnostics across routine pathology workflows in the USA.

Leica Biosystems and Indica Labs Expand Digital Pathology-Powered Diagnostics in the USA with Aperio HALO AP DX Software Launch Read More »

A lap top looking over the Sandia mountains in Albuquerque, NM; showcasing an IHC breast tissue image on the lap top screen with HER2 3+ stanning. Using AI and digital pathology for precision medicine, anytime anywhere.

AI and Digital Pathology in Personalized Medicine: The Past, Present, and Future of Breast Cancer Care

Blogs, Breast IHC AI, HALO AP, News / , , , , ,

AI-powered digital pathology is redefining modern cancer care by extending clinical-grade insights beyond the microscope and enabling standardized, pixel-level analysis to support scalable cancer diagnostics anytime, anywhere.

AI and Digital Pathology in Personalized Medicine: The Past, Present, and Future of Breast Cancer Care Read More »

HALO AP® earned 94.9/100* for overall customer rating in the 2026 Best in KLAS Awards - Global Software report for digital pathology.

KLAS Recognition as a Catalyst for What Comes Next

Blogs, HALO AP, News / ,

We are proud to mark a significant milestone: HALO AP® earned the highest overall customer rating in the 2026 KLAS Global Software report for digital pathology. Because KLAS distinction is driven entirely by direct customer feedback, this recognition reflects the real-world performance, reliability, and impact of our platform in daily pathology practice.

KLAS Recognition as a Catalyst for What Comes Next Read More »

Breast Macrodissect AI accurately identifies ductal carcinoma in situ (DCIS) and excludes this non-invasive region from invasive tumor analysis. Demonstrating the algorithm’s ability to differentiate between clinically relevant tissue architecture and improving molecular testing in breast cancer.

Indica Labs Sets New Standard for Molecular Testing in Breast Cancer with Expansion of AI Macrodissection Portfolio

Clinical, HALO AP, HALO Clinical AI, HALO Macrodissect Solutions, News, Press Releases / , , , ,

Albuquerque, NM, February 10, 2026 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced the expansion of its macrodissection portfolio with the launch of Breast Macrodissect AI . The suite now includes advanced algorithms for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and breast cancer, with prostate cancer planned for release in early 2026.

Indica Labs Sets New Standard for Molecular Testing in Breast Cancer with Expansion of AI Macrodissection Portfolio Read More »

The rapid global adoption of HALO AP® prompted immediate localization of the platform in Chinese, Danish, Dutch, American and British English, Finnish, French, German, Greek, Italian, Norwegian, Japanese, Portuguese, Russian, Spanish, Slovakian, and Swedish. Shown here are all 17 languages represented as each country's flags.

Indica Labs Reports 260% Clinical Revenue Growth and Expansion into New Global Markets

Breast IHC AI, HALO AP, HALO AP Dx, HALO Clinical AI, HALO Macrodissect Solutions, Lung Macrodissect AI, News, Press Releases / , , , , , , , ,

Albuquerque, NM, December 17, 2025 – Indica Labs, the global leader in AI-powered digital pathology, announced today that clinical revenue growth rate for HALO AP® is up 260% since 2023 and recurring revenue for 2025 shows a 200% increase year-over-year, reinforcing its position as a market leader in digital pathology diagnostics.

Indica Labs Reports 260% Clinical Revenue Growth and Expansion into New Global Markets Read More »

Indica Labs, HALO AP Dx, FDA 510(k)-cleared digital pathology platform displayed with the Aperio GT 450 DX Scanner for in vitro diagnostic use.

Indica Labs Receives FDA Clearance for Enterprise Digital Pathology Platform with Industry Leading DICOM-Compatible Aperio Scanner from Leica Biosystems

Clinical, HALO AP, HALO AP Dx, News, Press Releases / , ,

ALBUQUERQUE, NM, and VISTA, CA, December 3, 2025 – Indica Labs, the global leader of AI-powered digital pathology, and Leica Biosystems, a global leader in anatomic and digital pathology solutions, announced today that the Food and Drug Administration (FDA) has issued a 510(k) clearance for the enterprise digital pathology platform HALO AP Dx in conjunction with Leica Biosystems Aperio GT 450 DX Scanner for in-vitro diagnostic use.

Indica Labs Receives FDA Clearance for Enterprise Digital Pathology Platform with Industry Leading DICOM-Compatible Aperio Scanner from Leica Biosystems Read More »

Indica Labs' HER2 low and ultralow UI

Low and Ultralow HER2 Expression in Breast Cancer is Now Detectable by Indica Labs’ Breast IHC AI

Breast IHC AI, HALO AP, HALO Clinical AI, News, Press Releases / , , , , , ,

Albuquerque, NM, April 30, 2025 – Indica Labs, the leading provider of AI-powered digital pathology solutions, announces today an update to their Breast IHC AI suite, an image analysis tool used for the quantification of HER2, ER, PR, and Ki67 within AI-identified, tumor regions, of breast cancer tissue specimens. The HER2 algorithm will now include functionality for the detection of low and ultralow HER2 expression in breast cancer.

Low and Ultralow HER2 Expression in Breast Cancer is Now Detectable by Indica Labs’ Breast IHC AI Read More »

Free Demo
Free Demo
Scroll to Top